THE WHAT? Yatsen Group is pausing additional model acquisitions to pay attention funding on its current skincare portfolio, which now accounts for greater than 70 p.c of the Chinese language cosmetics group’s income.
THE DETAILS Quarterly skincare gross sales reached RMB 816 million (US$122 million), in contrast with skincare representing simply 12 p.c of group income when Yatsen listed in 2020. The corporate has remodeled its portfolio by way of acquisitions together with Galénic and Eve Lom and the mainland China rights to Dr Wu, whereas investing greater than RMB 700 million in R&D since 2020. Yatsen now plans to direct capital in direction of product formulation and natural model development somewhat than additional acquisitions. Nonetheless, profitability stays below stress, with second-quarter web losses widening to RMB 90.8 million as gross sales and advertising and marketing expenditure elevated 11.8 p.c to RMB 807.6 million, whereas color cosmetics income declined greater than 35 p.c.
THE WHY? The technique marks a shift from acquisition-led portfolio constructing in direction of natural development, R&D and better integration between Yatsen’s skincare and color cosmetics companies, together with plans to carry skincare substances and applied sciences into Excellent Diary make-up merchandise.
Supply: Retail Information Asia
